Since the depletion of SCs was achieved through a complicated genetic background (Sgcd−/−; Mapk3−/−; Mapk1f/f−Pax7Cre−ER), a simple depletion of SCs using mAbs is thought to be essential to obtain a proof of concept for the therapy of muscular dystrophy. This evidence concerns the gene MAPK3 and muscular dystrophy.